GlaxoSmithKline invests further £25 million in Scottish operation
UK pharma giant GlaxoSmithKline (LSE: GSK) is to invest £25 million ($40.2 million) to expand its operations in Montrose, Scotland, to support the delivery of its new pipeline of medicines.
In addition to the £2.7 million already ring fenced by the council, Scottish Enterprise is also backing the expansion by awarding Angus Council £1.5 million to improve access into the GSK site and the area around it. GSK is investing in new state of the art facilities and equipment to bring production of the ingredients for four new pharmaceutical products to Montrose.
Adds to £100 pledge in 2012
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze